 |
 |
2006
The future perspectives of breast cancer therapy
Chow LWC , Yiu CCP, Yip AYS and Loo WTY
Biomed Pharmacother. 2006 60(6):259-262. 
Details
Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer
Dewan MZ , Ahmed S, Iwasaki Y, Ohba K, Toi M and Yamamoto N
Biomed Pharmacother. 2006 60(6):273-276. Details
Anti-angiogenic and anti-HER therapy
Gasparini G , Sarmiento R and Longo R
Biomed Pharmacother. 2006 60(6):263-265. Details
A new predictive and prognostic marker (ATP bioluminescence and positron emission tomography) in vivo and in vitro for delivering adjuvant treatment plan to invasive breast tumor patients
Loo WTY , Tong JMK, Cheung MNB and Chow LWC
Biomed Pharmacother. 2006 60(6):285-288. Details
CD24 plays an important role in the carcinogenesis process of the pancreas
Sagiv E , Kazanov D and Arber N
Biomed Pharmacother. 2006 60(6): 280-284 Details
Chemoprevention of breast cancer among Asian women?its perspective and problems
Sasano H and Suzuki T
Biomed Pharmacother. 2006 60(6):266-268. Details
Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709
Siemeister G , Luecking U, Wagner C, Detjen K, Mc Coy C, and Bosslet K
Biomed Pharmacother. 2006 60(6):269-272. Details
Expression of survivin and clinical correlation in patients with breast cancer
Sohn DM , Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS and Kim TY
Biomed Pharmacother. 2006 60(6):289-292. Details
Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer
Suen D and Chow LWC
Biomed Pharmacother. 2006 60(6): 293-297 Details
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients
Ueno T , Chow LWC and Toi M
Biomed Pharmacother. 2006 60(6): 277-279 Details
